Generic Name and Formulations:
Lovastatin 20mg, 40mg, 60mg; ext-rel tabs.
Covis Pharmaceuticals, Inc.
Indications for ALTOPREV:
To reduce risk of MI, unstable angina, and coronary revascularization procedures in patients without coronary heart disease (CHD), but at high risk. To slow progression of coronary atherosclerosis in patients with CHD by lowering total-C and LDL-C. Adjunct to diet in primary hypercholesterolemia and mixed dyslipidemias (Types IIa and IIb) to lower elevated total-C, LDL-C, apo B, and TG, and to increase HDL-C, when response to nondrug therapy alone is inadequate. Limitations of use: not studied in Fredrickson Types I, III, and V dyslipidemias.
≥20yrs: 20–60mg once daily at bedtime. Elderly (≥65yrs): initially 20mg once daily at bedtime. Concomitant danazol, diltiazem, dronedarone, verapamil: max 20mg/day. Concomitant amiodarone: max 40mg/day. Severe renal impairment (CrCl<30mL/min): usual max 20mg/day.
<20yrs: not recommended.
Active liver disease. Unexplained persistent elevated hepatic transaminase levels. Pregnancy. Nursing mothers. Concomitant strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, clarithromycin, telithromycin, nefazodone), erythromycin.
Discontinue if myopathy suspected or elevated CPK levels occur; suspend if a predisposition to development of renal failure secondary to rhabdomyolysis develops. Monitor liver function before starting therapy and repeat as clinically indicated. Interrupt therapy if serious hepatic injury and/or hyperbilirubinemia, or jaundice occurs; do not restart if alternate etiology is not found. History of liver disease. Alcoholism. Females of reproductive potential should use effective contraception during treatment.
See Contraindications. Increased risk of myopathy with strong CYP3A4 inhibitors. Avoid gemfibrozil, cyclosporine, grapefruit juice >1 quart daily. Caution with other fibrates, niacin (≥1g/day), colchicine, ranolazine (lovastatin dose adjustment may be needed). Monitor with oral anticoagulants. Caution with drugs that may decrease levels or activity of endogenous steroid hormones (eg, spironolactone, cimetidine).
HMG-CoA reductase inhibitor.
Infection, headache, accidental injury, flu syndrome, pain, asthenia, arthralgia, myalgia, diarrhea, dizziness, sinusitis, urinary tract infection; elevated serum transaminases, myopathy, rhabdomyolysis with renal dysfunction, increases in HbA1c and fasting serum glucose levels; rare: immune-mediated necrotizing myopathy.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders